Heart Attack

Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment…

3 months ago

MyCardiologist Launches Immediate Care Clinic, Offering Same-Day Access to Expert Cardiac Care

MyCardiologistNow provides a new walk-in clinic for patients needing prompt evaluation of non-life-threatening heart symptomsMIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE)…

3 months ago

Digital Health Market worth US$573.5 billion by 2030 with 23.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Sept. 6, 2025 /PRNewswire/ -- The global Digital Health Market, valued at US$162.1 billion in 2024, stood…

3 months ago

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need  

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…

4 months ago

Howie’s 17+ Years After VesCell(TM): Following Hemostemix’s Heart Patients

Calgary, Alberta--(Newsfile Corp. - September 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…

4 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosingTxB2 is a biomarker…

4 months ago

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL…

4 months ago

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke…

4 months ago

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C)…

4 months ago

OMRON Healthcare Issues National Call-to-Action on Routine At-Home Blood Pressure Monitoring in Response to New Guidelines

Guideline Emphasis on Earlier Treatment to Reduce Health, Dementia Risks Boosts Urgency to Keep Closer Watch on Blood Pressure  OMRON…

4 months ago